Alchemab Therapeutics is a clinical-stage biotech discovering protective antibodies from disease-resilient individuals to develop novel therapeutics.
| Date | Round | Amount |
|---|---|---|
| Jul 2026 | Series A London biotech Alchemab Therapeutics extended its Series A with 29.3 million euros from the British Business Bank, the bank's largest life sciences investment, bringing total Series A funding to 127.8 million euros. | $34M |
Tap an investor to see what else they have backed.
Data is community-curated and may be incomplete.